Related Experiment Videos
[Cardiovascular manifestations associated with interferon alfa-2A]
E Mansat-Krzyzanowska1, B Dréno, A Chiffoleau
1Clinique Dermatologique, Hôtel-Dieu, Nantes.
Annales De Medecine Interne
|January 1, 1991
Summary
Interferon-alpha (IFN-α) can cause cardiovascular side effects, including rare heart blocks, even at low doses. Patients with pre-existing heart conditions require careful monitoring during IFN-α therapy.
Area of Science:
- Cardiology
- Pharmacology
- Dermatology
Background:
- Interferon-alpha (IFN-α) is a widely used therapeutic agent for viral and neoplastic conditions.
- The cardiovascular side effect profile of IFN-α is not fully elucidated.
- This study focuses on cardiovascular manifestations in patients receiving IFN-α 2a for dermatological conditions.
Observation:
- A cohort of 138 patients receiving IFN-α 2a between 1987 and 1990 underwent thorough cardiovascular assessments.
- Regular monitoring was conducted throughout the treatment period.
- Baseline cardiovascular examinations were performed prior to therapy initiation.
Findings:
- Six cardiac events (4.3%) were documented, including one case of complete atrioventricular block.
- Adverse events occurred at low doses (3-12 x 10^6 IU) in a predominantly elderly population (mean age 63 years).
- Five of the six affected patients had a history of prior cardiovascular incidents, suggesting potential predisposition.
Implications:
- These findings highlight the potential for significant cardiovascular side effects associated with interferon-alpha therapy.
- Prudent use and careful patient selection are advised, particularly in individuals with pre-existing cardiovascular disease.
- Further research into the mechanisms and risk factors for IFN-α-induced cardiotoxicity is warranted.